mirikizumab vs risankizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline

mirikizumab · Omvoh

Marketed by Eli Lilly

Approved in Ulcerative Colitismonoclonal antibody
Reliable signal

NCT03524092 · Phase 3 · completed

Randomized (re-randomization of induction responders), double-blind, placebo-controlled, adequately powered (n=544 in the key comparison), hard composite clinical/endoscopic primary endpoint that was statistically significant in the favorable direction (p<0.001) — meeting the 'strong' definition's full test.

Next expected readout: May 2027 · NCT07186101 (registry estimate)

Reported efficacy

Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders): Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders) (Week 40): Maintenance Period: Miri IR - 200 mg Miri SC 49.9% (95% CI 44.7 to 55) vs Maintenance Period: Miri IR - PBO SC 25.1% (95% CI 18.8 to 31.5) (met)

Result source: NCT03524092

risankizumab · Skyrizi

Marketed by AbbVie and partners

Approved in Ulcerative Colitismonoclonal antibody
Reliable signal

NCT03398148 · Phase 2/3 · completed

Design meets the 'strong' test: randomized, double-blind (participant and investigator masked), placebo-controlled, large adequately powered sample (n=1555 treated), hard clinical/endoscopic composite endpoint (Adapted Mayo Score remission including endoscopic subscore), and the primary comparison was statistically significant in the favorable direction for all randomized dose arms in both substudies.

Next expected readout: August 2027 · NCT06880744 (registry estimate)

Reported efficacy

clinical remission + endoscopic improvement met (met)

Result source: INSPIRE/COMMAND

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointmirikizumabrisankizumab
Clinical remission (induction)24.2% vs 13.3%+10.9 vs placebo300 mg IV Q4W · wk 12 · n 868NCT03518086
3 other results
  • 11.5% vs 4.8% 600 mg IV Q4W · wk 12 · n 61 · Phase 2 · primary NCT02589665
  • 22.6% vs 4.8% 200 mg IV Q4W · wk 12 · n 62 · Phase 2 · primary NCT02589665
  • 15.9% vs 4.8% 50 mg IV Q4W · wk 12 · n 63 · Phase 2 · primary NCT02589665
20.3% vs 6.2%+14.1 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
4 other results
  • 12.4% vs 1.7% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · primary NCT03398148
  • 9.8% vs 1.7% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148
  • 10.3% vs 1.7% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · primary NCT03398148
  • 11.5% vs 1.7% 600 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148
Clinical remission (maintenance)49.9% vs 25.1%+24.8 vs placebo200 mg SC · wk 40 · n 365NCT03524092—Trial running · NCT03398135
Clinical response (induction)63.5% vs 42.2%+21.3 vs placebo300 mg IV Q4W · wk 12 · n 868NCT03518086
3 other results
  • 49.2% vs 20.6% 600 mg IV Q4W · wk 12 · n 61 · Phase 2 · secondary NCT02589665
  • 59.7% vs 20.6% 200 mg IV Q4W · wk 12 · n 62 · Phase 2 · secondary NCT02589665
  • 41.3% vs 20.6% 50 mg IV Q4W · wk 12 · n 63 · Phase 2 · secondary NCT02589665
64.3% vs 35.7%+28.6 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
9 other results
  • 52.2% vs 30.5% 1200 mg IV · wk 4 · n 650 · Phase 2/3 · secondary NCT03398148
  • 46.2% vs 20% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · secondary NCT03398148
  • 43.5% vs 25% 1800 mg IV · wk 4 · n 340 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 20% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 25% 1200 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148
  • 53.4% vs 20% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · secondary NCT03398148
  • 37.9% vs 25% 1800 mg IV · wk 4 · n 58 · Phase 2/3 · secondary NCT03398148
  • 42.6% vs 20% 600 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 32.8% vs 25% 600 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148
Endoscopic improvement (induction)13.1% vs 6.3%+6.8 vs placebo600 mg IV Q4W · wk 12 · n 61NCT02589665
2 other results
  • 30.6% vs 6.3% 200 mg IV Q4W · wk 12 · n 62 · Phase 2 · secondary NCT02589665
  • 23.8% vs 6.3% 50 mg IV Q4W · wk 12 · n 63 · Phase 2 · secondary NCT02589665
36.5% vs 12.1%+24.4 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
Corticosteroid-free remission (maintenance)—Not posted · NCT05784246—Trial running · NCT03398135

Clinical remission (induction)

mirikizumab
24.2% vs 13.3%+10.9 vs placebo300 mg IV Q4W · wk 12 · n 868NCT03518086
3 other results
  • 11.5% vs 4.8% 600 mg IV Q4W · wk 12 · n 61 · Phase 2 · primary NCT02589665
  • 22.6% vs 4.8% 200 mg IV Q4W · wk 12 · n 62 · Phase 2 · primary NCT02589665
  • 15.9% vs 4.8% 50 mg IV Q4W · wk 12 · n 63 · Phase 2 · primary NCT02589665
risankizumab
20.3% vs 6.2%+14.1 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
4 other results
  • 12.4% vs 1.7% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · primary NCT03398148
  • 9.8% vs 1.7% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148
  • 10.3% vs 1.7% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · primary NCT03398148
  • 11.5% vs 1.7% 600 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148

Clinical remission (maintenance)

mirikizumab
49.9% vs 25.1%+24.8 vs placebo200 mg SC · wk 40 · n 365NCT03524092
risankizumab
—Trial running · NCT03398135

Clinical response (induction)

mirikizumab
63.5% vs 42.2%+21.3 vs placebo300 mg IV Q4W · wk 12 · n 868NCT03518086
3 other results
  • 49.2% vs 20.6% 600 mg IV Q4W · wk 12 · n 61 · Phase 2 · secondary NCT02589665
  • 59.7% vs 20.6% 200 mg IV Q4W · wk 12 · n 62 · Phase 2 · secondary NCT02589665
  • 41.3% vs 20.6% 50 mg IV Q4W · wk 12 · n 63 · Phase 2 · secondary NCT02589665
risankizumab
64.3% vs 35.7%+28.6 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
9 other results
  • 52.2% vs 30.5% 1200 mg IV · wk 4 · n 650 · Phase 2/3 · secondary NCT03398148
  • 46.2% vs 20% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · secondary NCT03398148
  • 43.5% vs 25% 1800 mg IV · wk 4 · n 340 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 20% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 25% 1200 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148
  • 53.4% vs 20% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · secondary NCT03398148
  • 37.9% vs 25% 1800 mg IV · wk 4 · n 58 · Phase 2/3 · secondary NCT03398148
  • 42.6% vs 20% 600 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 32.8% vs 25% 600 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148

Endoscopic improvement (induction)

mirikizumab
13.1% vs 6.3%+6.8 vs placebo600 mg IV Q4W · wk 12 · n 61NCT02589665
2 other results
  • 30.6% vs 6.3% 200 mg IV Q4W · wk 12 · n 62 · Phase 2 · secondary NCT02589665
  • 23.8% vs 6.3% 50 mg IV Q4W · wk 12 · n 63 · Phase 2 · secondary NCT02589665
risankizumab
36.5% vs 12.1%+24.4 vs placebo1200 mg IV · wk 12 · n 650NCT03398148

Corticosteroid-free remission (maintenance)

mirikizumab
—Not posted · NCT05784246
risankizumab
—Trial running · NCT03398135
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. mirikizumab: 5 of 5 rows · risankizumab: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricmirikizumab
Rows use multiple source trials
risankizumab
Endoscopic Remission
responder rate · % of participants
Induction
36.3% (n=868) vs 21.1% (n=294) placebo @ 12wk300 mg IV Q4Wa,b
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
3 other source trials
3.2% (n=62) vs 1.6% (n=63) placebo @ 12wk200 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
3.2% (n=63) vs 1.6% (n=63) placebo @ 12wk50 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
1.6% (n=61) vs 1.6% (n=63) placebo @ 12wk600 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
4.9% (n=61) vs 0% (n=60) placebo @ 12wk*1200 mg IVc,a,b
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 3 Participants as posted
show 4 more doses
10.6% (n=650) vs 3.4% (n=325) placebo @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.6% (n=58) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 5 Participants as posted
6.5% (n=340) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 22 Participants as posted
8.2% (n=61) vs 0% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 5 Participants as posted
Dropout rate
—300 mg IVd
NCT03524092 · Phase 3
show 30 more results
—300 mg IV
NCT03524092 · Phase 3
—300 mg IV
NCT03524092 · Phase 3
—300 mg IV
NCT03524092 · Phase 3
—200 mg SC
NCT03524092 · Phase 3
11.5%200 mg SC
NCT03524092 · Phase 3
—200 mg SC
NCT03524092 · Phase 3
—200 mg SC
NCT03524092 · Phase 3
—300 mg IV Q4W
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
4.1%300 mg IV Q4W
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
7.2%300 mg IV Q4W
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
9.9%300 mg
NCT05767021 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
0%300 mg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—300 mg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—300 mg IV / 200 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—200 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—100 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
0%10 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—10 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—10 mg/kg IV / 100 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—10 mg/kg IV / 50 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—5 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—5 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—200 mg SC Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
—200 mg SC Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
—200 mg SC Q12W
NCT02589665 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
—600 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
6.6%600 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
3.2%200 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
—50 mg Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
4.9%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 13 more results
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1.7%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
10.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
9.8%600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
Discontinued due to AEs
—300 mg IVd
NCT03524092 · Phase 3
show 30 more results
—300 mg IV
NCT03524092 · Phase 3
—300 mg IV
NCT03524092 · Phase 3
—300 mg IV
NCT03524092 · Phase 3
—200 mg SC
NCT03524092 · Phase 3
7.7%200 mg SC
NCT03524092 · Phase 3
—200 mg SC
NCT03524092 · Phase 3
—200 mg SC
NCT03524092 · Phase 3
—300 mg IV Q4W
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
1.6%300 mg IV Q4W
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
1.6%300 mg IV Q4W
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
1.2%300 mg
NCT05767021 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—300 mg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—300 mg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—300 mg IV / 200 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—200 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—100 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—10 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—10 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—10 mg/kg IV / 100 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—10 mg/kg IV / 50 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—5 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—5 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—200 mg SC Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
—200 mg SC Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
—200 mg SC Q12W
NCT02589665 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
—600 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
3.3%600 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
3.2%200 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
—50 mg Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
3.3%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 13 more results
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
0%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
2.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
3.3%600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
Serious AEs
5.2%300 mg IVd
NCT03524092 · Phase 3
show 30 more results
6.1%300 mg IV
NCT03524092 · Phase 3
3.3%300 mg IV
NCT03524092 · Phase 3
16.7%300 mg IV
NCT03524092 · Phase 3
3.3%200 mg SC
NCT03524092 · Phase 3
13.5%200 mg SC
NCT03524092 · Phase 3
3.3%200 mg SC
NCT03524092 · Phase 3
9.1%200 mg SC
NCT03524092 · Phase 3
2.8%300 mg IV Q4W
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—300 mg IV Q4W
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
8%300 mg IV Q4W
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
2.9%300 mg
NCT05767021 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
0%300 mg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
9.1%300 mg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—300 mg IV / 200 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—200 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—100 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
0%10 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
40%10 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—10 mg/kg IV / 100 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—10 mg/kg IV / 50 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
0%5 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
0%5 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
4.4%200 mg SC Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
4.3%200 mg SC Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
2.2%200 mg SC Q12W
NCT02589665 · Phase 2 · registry result, not featured evidence
5.2%1000 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
3.1%600 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
5%600 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
3.2%200 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
0%50 mg Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
6.6%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 13 more results
2.6%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1.5%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
2.3%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
9.9%360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1.4%360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.5%180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
5.6%180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.6%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
2.7%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
9.7%600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
Most frequent reported AEs
300 mg IVd
arthralgia 3.3% (placebo 4.2%)
nasopharyngitis 3.3% (placebo 5.7%)
headache 1.7% (placebo 1%)
NCT03524092 · Phase 3
show 24 more results
300 mg IV
upper respiratory tract infection 9.1% (placebo 2.6%)
anaemia 6.1% (placebo 4.7%)
covid-19 6.1% (placebo 2.1%)
NCT03524092 · Phase 3
300 mg IV
anaemia 5.6% (placebo 4.7%)
headache 5.6% (placebo 1%)
arthralgia 3.3% (placebo 4.2%)
NCT03524092 · Phase 3
300 mg IV
covid-19 8.3% (placebo 2.1%)
electrolyte imbalance 8.3% (placebo 0%)
haemorrhoids 8.3% (placebo 1.6%)
NCT03524092 · Phase 3
200 mg SC
nasopharyngitis 7.2% (placebo 5.7%)
arthralgia 6.7% (placebo 4.2%)
colitis ulcerative 6.7% (placebo 18.2%)
NCT03524092 · Phase 3
200 mg SC
upper respiratory tract infection 15.4% (placebo 2.6%)
covid-19 11.5% (placebo 2.1%)
abdominal pain 7.7% (placebo 2.1%)
NCT03524092 · Phase 3
200 mg SC
arthralgia 7% (placebo 4.2%)
nasopharyngitis 5.2% (placebo 5.7%)
headache 4.8% (placebo 1%)
NCT03524092 · Phase 3
200 mg SC
uterine leiomyoma 14.3% (placebo 0%)
upper respiratory tract infection 12.1% (placebo 2.6%)
anorectal polyp 6.1% (placebo 1%)
NCT03524092 · Phase 3
300 mg IV Q4W
anaemia 3.2% (placebo 5.6%)
colitis ulcerative 0% (placebo 0%)
upper respiratory tract infection 0% (placebo 0%)
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
300 mg IV Q4W
upper respiratory tract infection 12% (placebo 0%)
anaemia 6.4% (placebo 5.6%)
colitis ulcerative 2.4% (placebo 0%)
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
300 mg
any event 7%
any event 6.4%
any event 5.8%
NCT05767021 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
300 mg IV
rash 18.2%
dysmenorrhoea 16.7%
arthralgia 9.1%
NCT04004611 · Phase 2 · registry result, not featured evidence
300 mg IV
injection site pain 27.3%
asymptomatic covid-19 18.2%
covid-19 18.2%
NCT04004611 · Phase 2 · registry result, not featured evidence
10 mg/kg IV
anaemia 20%
covid-19 20%
pollakiuria 20%
NCT04004611 · Phase 2 · registry result, not featured evidence
10 mg/kg IV
covid-19 40%
anaemia 20%
dyspepsia 20%
NCT04004611 · Phase 2 · registry result, not featured evidence
5 mg/kg IV
headache 30%
pyrexia 20%
abdominal pain upper 10%
NCT04004611 · Phase 2 · registry result, not featured evidence
5 mg/kg IV
headache 30%
covid-19 20%
injection site pain 20%
NCT04004611 · Phase 2 · registry result, not featured evidence
200 mg SC Q4W
nasopharyngitis 20.6% (placebo 9.5%)
colitis ulcerative 10.3% (placebo 9.5%)
back pain 8.8% (placebo 0%)
NCT02589665 · Phase 2 · registry result, not featured evidence
200 mg SC Q4W
arthralgia 12.8% (placebo 0%)
nasopharyngitis 12.8% (placebo 9.5%)
headache 10.6% (placebo 4.8%)
NCT02589665 · Phase 2 · registry result, not featured evidence
200 mg SC Q12W
nasopharyngitis 17.4% (placebo 9.5%)
colitis ulcerative 15.2% (placebo 9.5%)
influenza 8.7% (placebo 0%)
NCT02589665 · Phase 2 · registry result, not featured evidence
1000 mg IV Q4W
nasopharyngitis 7.3% (placebo 9.5%)
dry skin 1% (placebo 0%)
abdominal discomfort 0% (placebo 0%)
NCT02589665 · Phase 2 · registry result, not featured evidence
600 mg IV Q4W
nasopharyngitis 15.6% (placebo 9.5%)
influenza 9.4% (placebo 0%)
dry skin 6.3% (placebo 0%)
NCT02589665 · Phase 2 · registry result, not featured evidence
600 mg IV Q4W
nasopharyngitis 8.3% (placebo 9.5%)
headache 6.7% (placebo 4.8%)
nausea 5% (placebo 6.3%)
NCT02589665 · Phase 2 · registry result, not featured evidence
200 mg IV Q4W
nasopharyngitis 4.8% (placebo 9.5%)
anaemia 3.2% (placebo 4.8%)
nausea 3.2% (placebo 6.3%)
NCT02589665 · Phase 2 · registry result, not featured evidence
50 mg Q4W
nasopharyngitis 7.9% (placebo 9.5%)
anaemia 6.3% (placebo 4.8%)
headache 4.8% (placebo 4.8%)
NCT02589665 · Phase 2 · registry result, not featured evidence
1200 mg IV
colitis ulcerative 4.9% (placebo 8.5%)
headache 4.9% (placebo 5.1%)
nasopharyngitis 4.9% (placebo 6.8%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 12 more results
1200 mg IV
covid-19 4.6% (placebo 0%)
anaemia 3.2% (placebo 3.4%)
headache 2.9% (placebo 5.1%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1200 mg IV
covid-19 5.9% (placebo 0%)
headache 2.9% (placebo 5.1%)
anaemia 1.5% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1200 mg IV
covid-19 5.7% (placebo 0%)
anaemia 2.9% (placebo 3.4%)
colitis ulcerative 1.7% (placebo 8.5%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
360 mg SC
nasopharyngitis 8.5% (placebo 6.8%)
headache 7% (placebo 5.1%)
colitis ulcerative 4.2% (placebo 8.5%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
360 mg SC
anaemia 8.5% (placebo 3.4%)
covid-19 8.5% (placebo 0%)
headache 8.5% (placebo 5.1%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
180 mg SC
headache 2.8% (placebo 5.1%)
anaemia 1.4% (placebo 3.4%)
nasopharyngitis 1.4% (placebo 6.8%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
180 mg SC
covid-19 5.6% (placebo 0%)
colitis ulcerative 4.2% (placebo 8.5%)
anaemia 2.8% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
nasopharyngitis 8.6% (placebo 6.8%)
headache 6.9% (placebo 5.1%)
anaemia 1.7% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
nasopharyngitis 7% (placebo 6.8%)
headache 6.5% (placebo 5.1%)
anaemia 3.5% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
nasopharyngitis 10.8% (placebo 6.8%)
anaemia 2.7% (placebo 3.4%)
colitis ulcerative 2.7% (placebo 8.5%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
dry skin 5.6% (placebo 0%)
headache 5.6% (placebo 5.1%)
nasopharyngitis 5.6% (placebo 6.8%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
600 mg IV
nasopharyngitis 8.1% (placebo 6.8%)
bronchitis 6.5% (placebo 0%)
dry skin 3.2% (placebo 0%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3

Notes

  1. aTrial phases differ: Phase 2/3 versus Phase 3.
  2. bTreatment context has not been resolved for both arms.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dPopulation comparability has not been reviewed for 27 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

mirikizumab

Clinical Remission 49.9% (n=365) vs 25.1% (n=179) placebo @ 40wk200 mg SC
responder rate · % of participants
Maintenance
NCT03524092 · Phase 3
Endoscopic Remission 58.6% (n=365) vs 29.1% (n=179) placebo @ 40wk200 mg SC
responder rate · % of participants
Maintenance
NCT03524092 · Phase 3
show 2 more results
14.9% (n=47) vs 7.7% (n=13) placebo @ 52wk200 mg SC Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
28.3% (n=46) vs 7.7% (n=13) placebo @ 52wk200 mg SC Q12W
NCT02589665 · Phase 2 · registry result, not featured evidence
Histologic Remission 48.5% (n=365) vs 24.6% (n=179) placebo @ 40wk200 mg SC
responder rate · % of participants
Maintenance
NCT03524092 · Phase 3
Symptomatic Remission 71% (n=365) vs 39.7% (n=179) placebo @ 40wk200 mg SC
responder rate · % of participants
Maintenance
NCT03524092 · Phase 3
show 2 more results
76.6% (n=47) vs 53.8% (n=13) placebo @ 52wk200 mg SC Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
65.2% (n=46) vs 53.8% (n=13) placebo @ 52wk200 mg SC Q12W
NCT02589665 · Phase 2 · registry result, not featured evidence
Endoscopic 72.6% (n=365) vs 40.8% (n=179) placebo @ 40wk200 mg SC
responder rate · % of participants
Maintenance
NCT03524092 · Phase 3
Clinical Response 80.3% (n=365) vs 49.2% (n=179) placebo @ 40wk200 mg SC
responder rate · % of participants
Maintenance
NCT03524092 · Phase 3
IBDQ 49.75 vs 24.51 placebo score @ 40wk200 mg SC
absolute change · score
Maintenance
NCT03524092 · Phase 3
Urgency NRS -3.8 vs -2.74 placebo score @ 40wk200 mg SC
absolute change · score
Maintenance
NCT03524092 · Phase 3
UC Hospitalization 0% (n=365) vs 1.1% (n=179) placebo @ 40wk200 mg SC
responder rate · % of participants
Maintenance
NCT03524092 · Phase 3
Symptomatic Remission 45.5% (n=868) vs 27.9% (n=294) placebo @ 12wk300 mg IV Q4W
responder rate · % of participants
Induction
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 3 more results
45.9% (n=61) vs 20.6% (n=63) placebo @ 12wk600 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
58.1% (n=62) vs 20.6% (n=63) placebo @ 12wk200 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
36.5% (n=63) vs 20.6% (n=63) placebo @ 12wk50 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
Symptomatic 72% (n=868) vs 52.4% (n=294) placebo @ 12wk300 mg IV Q4W
responder rate · % of participants
Induction
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Histologic Remission 29.3% (n=868) vs 15.6% (n=294) placebo @ 12wk300 mg IV Q4W
responder rate · % of participants
Induction
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3

+ 26 further endpoints in the CSV export.

risankizumab

Endoscopic Improvement 13.1% (n=61) vs 5% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 8 Participants as posted
show 3 more results
15.5% (n=58) vs 5% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 9 Participants as posted
17.9% (n=340) vs 5% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 61 Participants as posted
24.6% (n=61) vs 5% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 15 Participants as posted
UC-related Hospitalization 6.6% (n=61) vs 8.3% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 4 Participants as posted
show 3 more results
5.2% (n=58) vs 8.3% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 3 Participants as posted
5.6% (n=340) vs 8.3% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 19 Participants as posted
9.8% (n=61) vs 8.3% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 6 Participants as posted
HEMR 3.3% (n=61) vs 0% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 2 Participants as posted
show 3 more results
1.7% (n=58) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 1 Participants as posted
2.9% (n=340) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 10 Participants as posted
4.9% (n=61) vs 0% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 3 Participants as posted
UC-SQ -15.6 vs -7.4 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 3 more results
-15.1 vs -7.4 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
-17.1 vs -7.4 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
-13.8 vs -7.4 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
IBDQ 40.3 vs 20.1 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 4 more results
42.6 vs 24.3 placebo score @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
40 vs 20.1 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
49.5 vs 20.1 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
37.4 vs 20.1 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
SF-36 PCS 6.35 vs 3.904 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 3 more results
6.296 vs 3.904 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.719 vs 3.904 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
5.112 vs 3.904 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
SF-36 MCS 7.284 vs 3.094 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 3 more results
5.442 vs 3.094 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.777 vs 3.094 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
6.756 vs 3.094 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
FACIT-Fatigue 9 vs 3.7 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 4 more results
7.9 vs 3.3 placebo score @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.3 vs 3.7 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
10.7 vs 3.7 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.6 vs 3.7 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
UC-related Surgery 0% (n=61) vs 0% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 0 Participants as posted
show 3 more results
0% (n=58) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 0 Participants as posted
2.1% (n=340) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 7 Participants as posted
1.6% (n=61) vs 0% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 1 Participants as posted
HEMI 24.5% (n=650) vs 7.7% (n=325) placebo @ 12wk1200 mg IV
responder rate · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
No Bowel Urgency 44.1% (n=650) vs 27.7% (n=325) placebo @ 12wk1200 mg IV
responder rate · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
No Abdominal Pain 35.8% (n=650) vs 26.5% (n=325) placebo @ 12wk1200 mg IV
responder rate · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3

+ 4 further endpoints in the CSV export.

Crohn's Disease

Shared mechanism: IL-23 p19 · full Crohn's Disease pipeline

mirikizumab · Omvoh

Marketed by Eli Lilly

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

NCT03926130 · Phase 3 · completed

Randomized, triple-masked, placebo-controlled, adequately powered (n=1158 overall, ~778 in the placebo/mirikizumab primary comparison), with hard endoscopic (SES-CD response) and clinical remission co-primary endpoints, both meeting statistical significance (p<0.000001) favoring mirikizumab over placebo.

Next expected readout: September 2027 · NCT06997965 (registry estimate)

Reported efficacy

Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52); Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52): Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52): Placebo 9.0% (95% CI 5.1-13.0) vs Mirikizumab 38.0% (95% CI 34.0-42.0); p=<0.000001 (Placebo vs Mirikizumab) (met)

Result source: NCT03926130

risankizumab · Skyrizi

Marketed by AbbVie and partners

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

NCT03104413 · Phase 3 · completed

Design meets the 'strong' test: randomized, double-blind, placebo-controlled, adequately powered (n~600), with a hard endoscopic co-primary endpoint (SES-CD response) plus CDAI clinical remission, and both primary endpoint comparisons were statistically significant in the favorable direction for both doses vs placebo.

Next expected readout: March 2027 · NCT06063967 (registry estimate)

Reported efficacy

US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12); US Specific: Percentage of Participants With Endoscopic Response (Week 12); Global Outside of US: Percentage of Participants With Clinical Remission (Week 12); Global Outside of US: Percentage of Participants With Endoscopic Response (Week 12): US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Induction Period 1) 19.8% (95% CI 14.1-25.5) vs Risankizumab 600mg (Induction Period 1) 42.0% (95% CI 34.9-49.0) vs Risankizumab 1200mg (Induction Period 1) 40.3% (95% CI 33.4-47.3); p=<0.001 (Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1)), p=< 0.001 (Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1)) (met)

Result source: NCT03104413

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointmirikizumabrisankizumab
Clinical remission (induction)37.7% vs 25.1%+12.6 vs placebowk 12 · n 579NCT0392613042% vs 19.8%+22.2 vs placebo600 mg · wk 12 · n 191NCT03104413
26 other results
  • 28.8% vs 11.2% 600 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 45.2% vs 24.6% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 43.5% vs 21.7% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 40.3% vs 19.8% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 34.2% vs 11.2% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 41.6% vs 24.6% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 41% vs 21.7% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 34.6% vs 19.3% 600 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 42% vs 19.8% 600 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 43.5% vs 21.7% 600mg · wk 12 · n 336 · Phase 3 · secondary NCT03105128
  • 45.2% vs 24.6% 600mg · wk 12 · n 336 · Phase 3 · secondary NCT03105128
  • 20.9% vs 11.2% 600 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 17.3% vs 8% 600 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 18.4% vs 10.3% 600mg · wk 4 · n 336 · Phase 3 · secondary NCT03105128
  • 21% vs 9.1% 600mg · wk 4 · n 336 · Phase 3 · secondary NCT03105128
  • 39.8% vs 19.3% 1200 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 40.3% vs 19.8% 1200 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 41% vs 21.7% 1200mg · wk 12 · n 339 · Phase 3 · secondary NCT03105128
  • 41.6% vs 24.6% 1200mg · wk 12 · n 339 · Phase 3 · secondary NCT03105128
  • 19.4% vs 11.2% 1200 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 18.3% vs 8% 1200 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 18.9% vs 10.3% 1200mg · wk 4 · n 339 · Phase 3 · secondary NCT03105128
  • 21.2% vs 9.1% 1200mg · wk 4 · n 339 · Phase 3 · secondary NCT03105128
  • 36.6% vs 15.4% 600 mg IV · wk 12 · n 41 · Phase 2 · primary NCT02031276
  • 28% vs 15.4% 200 + 600 mg IV · wk 12 · n 82 · Phase 2 · primary NCT02031276
  • 19.5% vs 15.4% 200 mg IV · wk 12 · n 41 · Phase 2 · primary NCT02031276
Endoscopic response (induction)32.5% vs 12.6%+19.9 vs placebowk 12 · n 579NCT03926130
3 other results
  • 43.8% vs 10.9% 1000 mg IV Q4W · wk 12 · n 64 · Phase 2 · primary NCT02891226
  • 37.5% vs 10.9% 600 mg IV Q4W · wk 12 · n 32 · Phase 2 · primary NCT02891226
  • 25.8% vs 10.9% 200 mg IV Q4W · wk 12 · n 31 · Phase 2 · primary NCT02891226
28.8% vs 11.2%+17.6 vs placebo600 mg · wk 12 · n 191NCT03104413
10 other results
  • 34.6% vs 19.3% 600 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 40.3% vs 12% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 40.3% vs 12% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 34.2% vs 11.2% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 39.8% vs 19.3% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 32.1% vs 12% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 32.1% vs 12% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 36.6% vs 12.8% 600 mg IV · wk 12 · n 41 · Phase 2 · secondary NCT02031276
  • 31.7% vs 12.8% 200 + 600 mg IV · wk 12 · n 82 · Phase 2 · secondary NCT02031276
  • 26.8% vs 12.8% 200 mg IV · wk 12 · n 41 · Phase 2 · secondary NCT02031276
Clinical remission (maintenance)54.1% vs 19.6%+34.5 vs placebowk 52 · n 579NCT03926130—Trial running · NCT06063967
Endoscopic response (maintenance)48.4% vs 9%+39.4 vs placebowk 52 · n 579NCT03926130—Trial running · NCT06063967

Clinical remission (induction)

mirikizumab
37.7% vs 25.1%+12.6 vs placebowk 12 · n 579NCT03926130
risankizumab
42% vs 19.8%+22.2 vs placebo600 mg · wk 12 · n 191NCT03104413
26 other results
  • 28.8% vs 11.2% 600 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 45.2% vs 24.6% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 43.5% vs 21.7% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 40.3% vs 19.8% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 34.2% vs 11.2% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 41.6% vs 24.6% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 41% vs 21.7% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 34.6% vs 19.3% 600 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 42% vs 19.8% 600 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 43.5% vs 21.7% 600mg · wk 12 · n 336 · Phase 3 · secondary NCT03105128
  • 45.2% vs 24.6% 600mg · wk 12 · n 336 · Phase 3 · secondary NCT03105128
  • 20.9% vs 11.2% 600 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 17.3% vs 8% 600 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 18.4% vs 10.3% 600mg · wk 4 · n 336 · Phase 3 · secondary NCT03105128
  • 21% vs 9.1% 600mg · wk 4 · n 336 · Phase 3 · secondary NCT03105128
  • 39.8% vs 19.3% 1200 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 40.3% vs 19.8% 1200 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 41% vs 21.7% 1200mg · wk 12 · n 339 · Phase 3 · secondary NCT03105128
  • 41.6% vs 24.6% 1200mg · wk 12 · n 339 · Phase 3 · secondary NCT03105128
  • 19.4% vs 11.2% 1200 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 18.3% vs 8% 1200 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 18.9% vs 10.3% 1200mg · wk 4 · n 339 · Phase 3 · secondary NCT03105128
  • 21.2% vs 9.1% 1200mg · wk 4 · n 339 · Phase 3 · secondary NCT03105128
  • 36.6% vs 15.4% 600 mg IV · wk 12 · n 41 · Phase 2 · primary NCT02031276
  • 28% vs 15.4% 200 + 600 mg IV · wk 12 · n 82 · Phase 2 · primary NCT02031276
  • 19.5% vs 15.4% 200 mg IV · wk 12 · n 41 · Phase 2 · primary NCT02031276

Endoscopic response (induction)

mirikizumab
32.5% vs 12.6%+19.9 vs placebowk 12 · n 579NCT03926130
3 other results
  • 43.8% vs 10.9% 1000 mg IV Q4W · wk 12 · n 64 · Phase 2 · primary NCT02891226
  • 37.5% vs 10.9% 600 mg IV Q4W · wk 12 · n 32 · Phase 2 · primary NCT02891226
  • 25.8% vs 10.9% 200 mg IV Q4W · wk 12 · n 31 · Phase 2 · primary NCT02891226
risankizumab
28.8% vs 11.2%+17.6 vs placebo600 mg · wk 12 · n 191NCT03104413
10 other results
  • 34.6% vs 19.3% 600 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 40.3% vs 12% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 40.3% vs 12% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 34.2% vs 11.2% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 39.8% vs 19.3% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 32.1% vs 12% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 32.1% vs 12% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 36.6% vs 12.8% 600 mg IV · wk 12 · n 41 · Phase 2 · secondary NCT02031276
  • 31.7% vs 12.8% 200 + 600 mg IV · wk 12 · n 82 · Phase 2 · secondary NCT02031276
  • 26.8% vs 12.8% 200 mg IV · wk 12 · n 41 · Phase 2 · secondary NCT02031276

Clinical remission (maintenance)

mirikizumab
54.1% vs 19.6%+34.5 vs placebowk 52 · n 579NCT03926130
risankizumab
—Trial running · NCT06063967

Endoscopic response (maintenance)

mirikizumab
48.4% vs 9%+39.4 vs placebowk 52 · n 579NCT03926130
risankizumab
—Trial running · NCT06063967
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. mirikizumab: 6 of 6 rows · risankizumab: 5 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricmirikizumab
Rows use multiple source trials
risankizumab
Rows use multiple source trials
Endoscopic Remission
responder rate · % of participants
Induction
10.9% (n=579) vs 4% (n=199) placebo @ 12wka,b
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 1 more dose
17.6% (n=579) vs 7% (n=199) placebo @ 12wk
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
19.4% (n=191) vs 4.3% (n=187) placebo @ 12wk600 mga,b
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 3 more doses
19.4% (n=191) vs 4.3% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
20.4% (n=191) vs 4.3% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
20.4% (n=191) vs 4.3% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
FACIT-Fatigue
absolute change · score
Induction
9.62 vs 2.9 placebo score @ 12wk1000 mg IV Q4Wa,c,d,b
NCT02891226 · Phase 2 · registry result, not featured evidence
show 2 more doses
9.09 vs 2.9 placebo score @ 12wk600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
10.81 vs 2.9 placebo score @ 12wk200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
11.2 vs 6 placebo score @ 12wk600mga,c,d,b
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
show 1 more dose
10.1 vs 6 placebo score @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
Dropout rate
11.1%Mirikizumabe
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 16 more results
33.3%Mirikizumab (Adolescents)
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—300 mg SC Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—300 mg SC Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—300 mg SC Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
6.3%1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
12.5%600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
6.5%200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
1.9%600 mgf
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 16 more results
—360 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—180 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
2.9%1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—600mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—360mg SC
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—180mg SC
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—600 mg IV
NCT02513459 · Phase 2 · registry result, not featured evidence
—180 mg SC
NCT02513459 · Phase 2 · registry result, not featured evidence
—600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
—600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
—180 mg SC
NCT02031276 · Phase 2 · registry result, not featured evidence
—200 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
1.7%Mirikizumabe
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 16 more results
0%Mirikizumab (Adolescents)
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—300 mg SC Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—300 mg SC Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—300 mg SC Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
0%1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
9.4%600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
3.2%200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—600 mgf
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 16 more results
—360 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—180 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—600mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—360mg SC
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—180mg SC
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—600 mg IV
NCT02513459 · Phase 2 · registry result, not featured evidence
—180 mg SC
NCT02513459 · Phase 2 · registry result, not featured evidence
—600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
—600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
—180 mg SC
NCT02031276 · Phase 2 · registry result, not featured evidence
—200 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
Serious AEs
10.3%Mirikizumabe
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 16 more results
0%Mirikizumab (Adolescents)
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
0%300 mg SC Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
4.3%300 mg SC Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
11%300 mg SC Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
0%1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
0%1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
0%1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
3.1%1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
0%1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
10%1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
15.3%1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
9.4%600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
0%600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
0%200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
0%200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
0%200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
4.9%600 mgf
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 16 more results
4.8%360 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
4.9%180 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
4.4%1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
7.1%1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
7.2%600mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
4.4%360mg SC
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
4.5%180mg SC
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
3.8%1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
5.3%1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
6%1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
0%600 mg IV
NCT02513459 · Phase 2 · registry result, not featured evidence
35.4%180 mg SC
NCT02513459 · Phase 2 · registry result, not featured evidence
9.8%600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
10.9%600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
11.3%180 mg SC
NCT02031276 · Phase 2 · registry result, not featured evidence
24.4%200 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
e
covid-19 16.3% (placebo 10%)
anaemia 6.8% (placebo 4.7%)
arthralgia 6.5% (placebo 4.7%)
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 16 more results
arthralgia 16.7% (placebo 4.7%)
covid-19 16.7% (placebo 10%)
crohn's disease 16.7% (placebo 10%)
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
300 mg SC Q4W
abdominal distension 0% (placebo 0%)
abdominal pain 0% (placebo 1.6%)
alanine aminotransferase increased 0% (placebo 0%)
NCT02891226 · Phase 2 · registry result, not featured evidence
300 mg SC Q4W
arthralgia 13% (placebo 4.7%)
nasopharyngitis 13% (placebo 1.6%)
headache 8.7% (placebo 3.1%)
NCT02891226 · Phase 2 · registry result, not featured evidence
300 mg SC Q4W
nasopharyngitis 18.4% (placebo 1.6%)
injection site reaction 13.2% (placebo 0%)
headache 11.8% (placebo 3.1%)
NCT02891226 · Phase 2 · registry result, not featured evidence
1000 mg IV Q4W
vitamin d deficiency 50% (placebo 0%)
abdominal distension 0% (placebo 0%)
abdominal pain 0% (placebo 1.6%)
NCT02891226 · Phase 2 · registry result, not featured evidence
1000 mg IV Q4W
crohn's disease 100% (placebo 9.4%)
respiratory tract infection viral 100% (placebo 1.6%)
abdominal distension 0% (placebo 0%)
NCT02891226 · Phase 2 · registry result, not featured evidence
1000 mg IV Q4W
abdominal distension 0% (placebo 0%)
abdominal pain 0% (placebo 1.6%)
alanine aminotransferase increased 0% (placebo 0%)
NCT02891226 · Phase 2 · registry result, not featured evidence
1000 mg IV Q4W
headache 10.9% (placebo 3.1%)
nasopharyngitis 6.3% (placebo 1.6%)
arthralgia 4.7% (placebo 4.7%)
NCT02891226 · Phase 2 · registry result, not featured evidence
1000 mg IV Q4W
headache 13% (placebo 3.1%)
epididymitis 9.1% (placebo 0%)
abdominal pain 8.7% (placebo 1.6%)
NCT02891226 · Phase 2 · registry result, not featured evidence
1000 mg IV Q4W
headache 10% (placebo 3.1%)
nasopharyngitis 10% (placebo 1.6%)
anaemia 6.7% (placebo 1.6%)
NCT02891226 · Phase 2 · registry result, not featured evidence
1000 mg IV Q4W
anaemia 8.5% (placebo 1.6%)
fatigue 6.8% (placebo 4.7%)
headache 6.8% (placebo 3.1%)
NCT02891226 · Phase 2 · registry result, not featured evidence
600 mg IV Q4W
pyrexia 9.4% (placebo 1.6%)
weight increased 9.4% (placebo 0%)
abdominal distension 6.3% (placebo 0%)
NCT02891226 · Phase 2 · registry result, not featured evidence
600 mg IV Q4W
vulvovaginal mycotic infection 25% (placebo 2.8%)
anal incontinence 11.1% (placebo 0%)
anxiety 11.1% (placebo 1.6%)
NCT02891226 · Phase 2 · registry result, not featured evidence
200 mg IV Q4W
abdominal distension 0% (placebo 0%)
abdominal pain 0% (placebo 1.6%)
alanine aminotransferase increased 0% (placebo 0%)
NCT02891226 · Phase 2 · registry result, not featured evidence
200 mg IV Q4W
alanine aminotransferase increased 6.5% (placebo 0%)
anaemia 6.5% (placebo 1.6%)
aspartate aminotransferase increased 6.5% (placebo 0%)
NCT02891226 · Phase 2 · registry result, not featured evidence
200 mg IV Q4W
abdominal pain 11.1% (placebo 1.6%)
anaemia 11.1% (placebo 1.6%)
arthralgia 11.1% (placebo 4.7%)
NCT02891226 · Phase 2 · registry result, not featured evidence
600 mgf
headache 5.3% (placebo 5.3%)
arthralgia 3.9% (placebo 3.9%)
nasopharyngitis 3.9% (placebo 5.3%)
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 16 more results
360 mg
arthralgia 2.4% (placebo 3.9%)
headache 2.4% (placebo 5.3%)
nausea 2.4% (placebo 4.8%)
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
180 mg
arthralgia 4.9% (placebo 3.9%)
crohn's disease 2.4% (placebo 6.3%)
headache 2.4% (placebo 5.3%)
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
1200 mg
headache 4.9% (placebo 5.3%)
arthralgia 4.4% (placebo 3.9%)
nasopharyngitis 3.9% (placebo 5.3%)
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
1200 mg
headache 7.1% (placebo 5.3%)
nausea 7.1% (placebo 4.8%)
crohn's disease 4.8% (placebo 6.3%)
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
600mg IV
headache 6.4% (placebo 4.3%)
nasopharyngitis 5.9% (placebo 2.7%)
nausea 4.3% (placebo 5.4%)
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
360mg SC
headache 4.4% (placebo 4.3%)
anaemia 2.9% (placebo 2.7%)
crohn's disease 1.5% (placebo 5.4%)
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
180mg SC
crohn's disease 3% (placebo 5.4%)
headache 1.5% (placebo 4.3%)
nasopharyngitis 1.5% (placebo 2.7%)
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
1200mg IV
nasopharyngitis 5.9% (placebo 2.7%)
headache 5.4% (placebo 4.3%)
nausea 3.5% (placebo 5.4%)
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
1200mg IV
headache 6.6% (placebo 4.3%)
anaemia 5.3% (placebo 2.7%)
nausea 3.9% (placebo 5.4%)
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
1200mg IV
headache 3% (placebo 4.3%)
anaemia 1.5% (placebo 2.7%)
nasopharyngitis 1.5% (placebo 2.7%)
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
600 mg IV
abdominal pain upper 25%
ear pain 25%
haematochezia 25%
NCT02513459 · Phase 2 · registry result, not featured evidence
180 mg SC
nasopharyngitis 30.8%
gastroenteritis 23.1%
fatigue 20%
NCT02513459 · Phase 2 · registry result, not featured evidence
600 mg IV
arthralgia 19.5% (placebo 10.3%)
headache 12.2% (placebo 12.8%)
abdominal pain 9.8% (placebo 12.8%)
NCT02031276 · Phase 2 · registry result, not featured evidence
600 mg IV
abdominal pain 10.9% (placebo 12.8%)
nasopharyngitis 7.9% (placebo 7.7%)
arthralgia 6.9% (placebo 10.3%)
NCT02031276 · Phase 2 · registry result, not featured evidence
180 mg SC
nasopharyngitis 14.5% (placebo 7.7%)
arthralgia 9.7% (placebo 10.3%)
headache 9.7% (placebo 12.8%)
NCT02031276 · Phase 2 · registry result, not featured evidence
200 mg IV
nausea 22% (placebo 10.3%)
abdominal pain 14.6% (placebo 12.8%)
arthralgia 14.6% (placebo 10.3%)
NCT02031276 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTreatment context has not been resolved for both arms.
  3. cTrial phases differ: Phase 3 versus Phase 2.
  4. dPopulation comparability has not been reviewed for both studies.
  5. ePopulation comparability has not been reviewed for 15 of these studies.
  6. fPopulation comparability has not been reviewed for 6 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

mirikizumab

Clinical Response and Endoscopic Response Composite 38% (n=579) vs 9% (n=199) placebo @ 52wk
responder rate · % of participants
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Clinical Response and Clinical Remission Composite 45.4% (n=579) vs 19.6% (n=199) placebo @ 52wk
responder rate · % of participants
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 1 more result
45.4% (n=579) vs 19.6% (n=199) placebo @ 52wk
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Urgency NRS -2.44 vs -1.58 placebo score @ 12wk
absolute change · score
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 1 more result
-3.24 vs -1.23 placebo score @ 52wk
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Clinical Response and Endoscopic Remission Composite 15.9% (n=579) vs 2% (n=199) placebo @ 52wk
responder rate · % of participants
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 1 more result
23.5% (n=579) vs 4% (n=199) placebo @ 52wk
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Clinical Response and Corticosteroid-free Clinical Remission Composite 43.7% (n=579) vs 18.6% (n=199) placebo @ 52wk
responder rate · % of participants
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Clinical Response and EIM Resolution Composite 43.2% (n=132) vs 14.6% (n=41) placebo @ 52wk
responder rate · % of participants
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Clinical Response and Fistula Reduction Composite 21.1% (n=38) vs 16.7% (n=18) placebo @ 52wk
responder rate · % of participants
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
PRO-2 Remission 21.9% (n=64) vs 6.3% (n=64) placebo @ 12wk1000 mg IV Q4W
responder rate · % of participants
NCT02891226 · Phase 2 · registry result, not featured evidence
show 2 more results
28.1% (n=32) vs 6.3% (n=64) placebo @ 12wk600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
12.9% (n=31) vs 6.3% (n=64) placebo @ 12wk200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
PGI-S -0.98 vs -0.44 placebo score @ 12wk1000 mg IV Q4W
absolute change · score
NCT02891226 · Phase 2 · registry result, not featured evidence
show 2 more results
-1.27 vs -0.44 placebo score @ 12wk600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
-1.08 vs -0.44 placebo score @ 12wk200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
PGIC 2.5 vs 3.6 placebo score @ 12wk1000 mg IV Q4W
absolute value · score
NCT02891226 · Phase 2 · registry result, not featured evidence
show 2 more results
2.6 vs 3.6 placebo score @ 12wk600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
2.8 vs 3.6 placebo score @ 12wk200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
IBDQ 42.35 vs 17.11 placebo score @ 12wk1000 mg IV Q4W
absolute change · score
NCT02891226 · Phase 2 · registry result, not featured evidence
show 2 more results
46.57 vs 17.11 placebo score @ 12wk600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
41.16 vs 17.11 placebo score @ 12wk200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence

risankizumab

CDAI 36.6% (n=191) vs 20.9% (n=187) placebo @ 4wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 15 more results
59.5% (n=191) vs 30% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
36.6% (n=191) vs 20.9% (n=187) placebo @ 4wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
59.5% (n=191) vs 30% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
40.8% (n=336) vs 25.2% (n=175) placebo @ 4wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
59.7% (n=336) vs 36.7% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
40.8% (n=336) vs 25.2% (n=175) placebo @ 4wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
59.7% (n=336) vs 36.7% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
32.5% (n=191) vs 20.9% (n=187) placebo @ 4wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
60.7% (n=191) vs 30% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
32.5% (n=191) vs 20.9% (n=187) placebo @ 4wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
60.7% (n=191) vs 30% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
37.2% (n=339) vs 25.2% (n=175) placebo @ 4wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
64.9% (n=339) vs 36.7% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
37.2% (n=339) vs 25.2% (n=175) placebo @ 4wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
64.9% (n=339) vs 36.7% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
CDAI Response and Endoscopic 20.5% (n=191) vs 5.3% (n=187) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 3 more results
30% (n=336) vs 5.7% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
23% (n=191) vs 5.3% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
23% (n=339) vs 5.7% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
Stool Frequency Remission 46.1% (n=191) vs 28.3% (n=187) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 3 more results
54.2% (n=336) vs 29.8% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
48.7% (n=191) vs 28.3% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
54% (n=339) vs 29.8% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
Abdominal Pain Remission 58.1% (n=191) vs 36.4% (n=187) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 3 more results
59.6% (n=336) vs 38.5% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
59.2% (n=191) vs 36.4% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
58.1% (n=339) vs 38.5% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
Enhanced Clinical 45% (n=191) vs 31.6% (n=187) placebo @ 4wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 15 more results
61.8% (n=191) vs 39.1% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
45% (n=191) vs 31.6% (n=187) placebo @ 4wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
61.8% (n=191) vs 39.1% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
46% (n=336) vs 31% (n=175) placebo @ 4wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
62.8% (n=336) vs 41.9% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
46% (n=336) vs 31% (n=175) placebo @ 4wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
62.8% (n=336) vs 41.9% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
38.7% (n=191) vs 31.6% (n=187) placebo @ 4wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
59.2% (n=191) vs 39.1% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
38.7% (n=191) vs 31.6% (n=187) placebo @ 4wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
59.2% (n=191) vs 39.1% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
43.4% (n=339) vs 31% (n=175) placebo @ 4wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
64.3% (n=339) vs 41.9% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
43.4% (n=339) vs 31% (n=175) placebo @ 4wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
64.3% (n=339) vs 41.9% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
Ulcer-Free Endoscopy 13.8% (n=190) vs 4.3% (n=186) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 7 more results
13.8% (n=190) vs 4.3% (n=186) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
21% (n=336) vs 7.6% (n=173) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
21% (n=336) vs 7.6% (n=173) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
15.4% (n=189) vs 4.3% (n=186) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
15.4% (n=189) vs 4.3% (n=186) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
16.4% (n=339) vs 7.6% (n=173) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
16.4% (n=338) vs 7.6% (n=173) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
EIM Resolution 29.5% (n=100) vs 23.7% (n=97) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 7 more results
29.5% (n=100) vs 23.7% (n=97) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
38.1% (n=140) vs 20.5% (n=64) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
38.1% (n=140) vs 20.5% (n=64) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
37.1% (n=97) vs 23.7% (n=97) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
37.1% (n=97) vs 23.7% (n=97) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
43.7% (n=158) vs 20.5% (n=64) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
43.7% (n=158) vs 20.5% (n=64) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
CD-Related Hospitalization 3.1% (n=191) vs 11.2% (n=187) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 7 more results
3.1% (n=191) vs 11.2% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
3.3% (n=339) vs 12% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
3.3% (n=336) vs 12% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
2.1% (n=191) vs 11.2% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
2.1% (n=191) vs 11.2% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
1.8% (n=339) vs 12% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
1.8% (n=339) vs 12% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
Draining Fistula Closure 7.1% (n=14) vs 13.3% (n=15) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 7 more results
7.1% (n=14) vs 13.3% (n=15) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
27.8% (n=18) vs 22.2% (n=9) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
27.8% (n=18) vs 22.2% (n=9) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
43.8% (n=16) vs 13.3% (n=15) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
43.8% (n=16) vs 13.3% (n=15) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
29.2% (n=24) vs 22.2% (n=9) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
29.2% (n=24) vs 22.2% (n=9) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
Enhanced Clinical Response and Endoscopic 21% (n=191) vs 7% (n=187) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 3 more results
30.9% (n=336) vs 8% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
24.1% (n=191) vs 7% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
23.2% (n=339) vs 8% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
WPAI-CD Overall Work Impairment -19.576 vs -12.253 placebo score @ 12wk600 mg
absolute change · score
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 3 more results
-17.93 vs -8.344 placebo score @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
-21.013 vs -12.253 placebo score @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
-20.485 vs -8.344 placebo score @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
SF-36 PCS 7.458 vs 5.237 placebo score @ 12wk600 mg
absolute change · score
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 3 more results
8.394 vs 5.482 placebo score @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
7.951 vs 5.237 placebo score @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
8.756 vs 5.482 placebo score @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3

+ 27 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: mirikizumab's landscape · risankizumab's landscape